To identify a therapeutic oligonucleotide with the right drug-like properties, a large number of oligonucleotides are usually screened. However, many more oligonucleotides can be designed against a target than can practically be screened (see previous blog). So how should we select oligonucleotides for a screening campaign among the vast number of possibilities?
In early April, the Cold Spring Harbor Laboratory will host a conference on RNA and oligonucleotide therapeutics. Some of the research done in COAT to address this issue will be presented at the conference.
Morten will be giving a talk, where he demonstrate that the sequence-nature of oligonucleotides, combined with data from a large number of screening
All abstracts for the meeting can be seen here. We look forward to the talk by our colleague Dr. Susanna Obad from Santaris Pharma, presenting data on the treatment of hepatitis C infected patients with the antimiR oligonucleotide Miravirsen.
We are excited to participate and contribute with some of our research at the meeting. See you there!